Trump's FDA pick Overton may boost psychedelics, pain meds

President Donald Trump has announced his intention to nominate Heidi Overton as the next commissioner of the U.S. Food and Drug Administration (FDA). This move, revealed on Trump's Truth Social platform, signals potential shifts in the agency's approach to psychedelic therapies and non-opioid pain medications, according to analysts.

Overton's Role in Psychedelic Therapies

Overton, currently a White House policy advisor, has been instrumental in shaping policies that could accelerate the development of psychedelic therapies. According to BMO Capital Markets, her involvement in an April 2026 executive order prioritizing FDA review of ibogaine and MDMA-based therapies underscores the administration's commitment to exploring psychedelics as medical treatments. This could benefit companies like Compass Pathways, which is developing a psilocybin-based therapy for treatment-resistant depression.

Support for Non-Opioid Pain Medications

Overton's nomination is also seen as a potential boost for non-opioid pain medication initiatives. Since the approval of Vertex Pharmaceuticals' Journavx in January 2025, the field has gained momentum, with companies like AbbVie entering the space. Overton's past work with former FDA Commissioner Marty Makary on opioid prescribing aligns with this agenda, potentially supporting further development of alternatives to opioid painkillers.

Concerns Over Vaccine Policies

Despite potential advancements in other areas, Overton's stance on vaccines has raised concerns. Her involvement in executive orders that could alter the childhood vaccine schedule has led analysts to caution vaccine makers like Merck, Pfizer, and BioNTech about potential regulatory risks. Overton's presence at a recent executive order signing, which suggested changes to the MMR vaccine, has further fueled these concerns.

Why It Matters

Overton's nomination could significantly impact the FDA's direction, particularly in the areas of psychedelic therapies and non-opioid pain medications. However, her approach to vaccines may introduce regulatory uncertainties for pharmaceutical companies. As the first woman to potentially lead the FDA since 2015, Overton's confirmation could mark a pivotal moment in the agency's history.

Heidi Overton's nomination reflects broader trends in healthcare policy under the current administration, emphasizing innovation in some areas while raising questions in others.